Acrobat Genomics Inc. is a California-based biotechnology company founded in 2022 as a Stanford University spinout. Firm specializes in developing safer, high-throughput CRISPR gene-editing therapeutics for genetic diseases, using machine learning-guided protein design to accelerate drug discovery. Firm was selected for the Illumina Accelerator's fifth global funding cycle in 2022. Developing precision gene-editing therapies, with early efforts targeting ALS (amyotrophic lateral sclerosis) by optimizing RNA-guided nucleases to target C9ORF72 transcripts. Technology: Leverages a proprietary platform combining machine learning, deep mutational scanning, and parallel DNA repair measurements to enhance the precision and efficiency of CRISPR/Cas9 technology. Leadership/Funding: company secured seed investment from Illumina Accelerator and Taihill Venture. Development Speed: Reported producing a proof-of-concept asset in approximately 6 months. Management aim significantly to reduce the time and cost associated with conventional drug development, which often takes over a decade.
